The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, according to a press release.
Yuflyma (adalimumab-aaty, Celltrion, Inc.), approved May 21 as a fully interchangeable biosimilar to Humira across dosage forms and strengths, is indicated for multiple diseases including psoriatic arthritis, plaque psoriasis and rheumatoid arthritis, in addition to HS and uveitis in adults.
“Adolescent HS and pediatric uveitis are chronic inflammatory conditions that can